SPONSOR
Hackensack Meridian Health
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 2, Phase 2
Hackensack Meridian Health is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Lung Cancer, Urinary Retention, Multiple Myeloma.
The trial portfolio spans Phase 1, Phase 2, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Hackensack Meridian Health
How many clinical trials has Hackensack Meridian Health sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Hackensack Meridian Health, of which 3 are actively recruiting participants. These trials cover conditions including Lung Cancer, Urinary Retention, Multiple Myeloma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Hackensack Meridian Health research focus on?
Hackensack Meridian Health clinical trials span Lung Cancer, Urinary Retention, Multiple Myeloma. The research pipeline includes Phase 1, Phase 2, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Hackensack Meridian Health clinical trial?
To participate in a Hackensack Meridian Health trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Hackensack Meridian Health trials with current recruitment status updated daily.
Clinical Trials by Hackensack Meridian Health
NCT06199570
Recruiting
Support for Cancer Patients Awaiting News
Lung Cancer
NCT03609580 Phase 1, Phase 2
Recruiting
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
Urinary Retention
NCT04661137 Phase 2
Recruiting
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Multiple Myeloma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology